Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-123264
Filing Date
2024-11-07
Accepted
2024-11-07 16:05:01
Documents
58
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q phat-20240930.htm   iXBRL 10-Q 1963654
2 EX-10.1 phat-ex10_1.htm EX-10.1 32242
3 EX-31.1 phat-ex31_1.htm EX-31.1 14477
4 EX-31.2 phat-ex31_2.htm EX-31.2 14537
5 EX-32.1 phat-ex32_1.htm EX-32.1 8459
6 EX-32.2 phat-ex32_2.htm EX-32.2 8502
7 GRAPHIC img229110809_0.jpg GRAPHIC 4208
  Complete submission text file 0000950170-24-123264.txt   8696991

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT phat-20240930.xsd EX-101.SCH 1564656
61 EXTRACTED XBRL INSTANCE DOCUMENT phat-20240930_htm.xml XML 1227928
Mailing Address 100 CAMPUS DRIVE, SUITE 102 FLORHAM PARK NJ 07932
Business Address 100 CAMPUS DRIVE, SUITE 102 FLORHAM PARK NJ 07932 (877) 742-8466
Phathom Pharmaceuticals, Inc. (Filer) CIK: 0001783183 (see all company filings)

EIN.: 824151574 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39094 | Film No.: 241435483
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)